Posted on: 19/05/2026

AMMA Medtech Showcase Spotlights Procurement Shift

Something shifted at the AMMA Medtech Showcase and it’s hard not to feel optimistic about what’s coming

180+ delegates, 21 exhibitors, 7 Pathway to Market pitches and a packed program focused on one question: how do we get more Australian medtech innovations adopted into our own health system?

A standout opening discussion between Prof Euan Wallace AM and Prof Ian Meredith highlighted three clear themes:

1. Stronger commitment from health services and government to adopt local innovation, backed by clear measures and accountability.
2. Health system consolidation in Victoria from 74 entities to 15 Local Health Service Networks could simplify governance, reduce fragmentation and barriers to evaluation and adoption.
3. More structured engagement between clinicians and industry so both sides understand each other’s challenges, unmet needs and emerging innovations.

HealthShare Victoria Chief Procurement Officer Sarah Bryant gave us an honest look at where procurement is heading – better data, stronger supplier relationships and a new supply relationship management function by 2027. Reform is underway.

Kerryn Greive from Ego Pharmaceuticals spoke to the power of local manufacturing of their skin and healthcare range, founded on science, and now exporting products to 25 nations across the globe for over 70 years.

MTPConnect CEO and MD Stuart Dignam reinforced the importance of creating clearer, more consistent pathways for local innovators to engage with the health system highlighting that the Pathway to Market program’s success.

In a recent story published by InnovationAus, Closing Australia’s medtech gap starts with procurement, Stuart had this to say.

“A purchase order is often better than a grant”.

“Grants help innovation, but purchase orders send a stronger signal. They provide validation that something works, is safe, and is trusted in clinical settings. They also signal to investors that the product is worth backing,” he said.

Big congratulations to the Pathway to Market cohort companies who pitched and showcased their innovations throughout the day:

4DMedical | Arelis | Lenexa Medical | Mediklean | MX3 Diagnostics | Proton Intelligence | Sadleir Laboratories 

These companies are tackling major healthcare challenges across imaging, diagnostics, infection control, chronic disease monitoring, women’s health, pressure injury prevention and safer medication delivery all while building sovereign manufacturing capability here in Victoria.

To tie up the day, a roundtable with delegates, led by MTPConnect’s Dr Dharmica Mistry, alongside Andrew Coe (Monash Health) and Valentina Trajkovski (Western Health), explored how co-design between clinicians, procurement and industry can shape the health system we want.

A huge thank you to all exhibitors, speakers, delegates, partners and the teams behind the scenes who helped bring the event to life including BioMelbourne Network, the Victorian Government and the broader Australian Medtech Manufacturing Alliance initiative.

Keep an eye out for a special MTPConnect Podcast episode coming soon featuring insights from this incredible cohort and event.

Better Health Made Here.